Durvalumab with chemotherapy for neoadjuvant and adjuvant treatment then alone for adjuvant treatment of resectable gastric or gastro-oesophageal junction adenocarcinoma

Durvalumab (Imfinzi, AstraZeneca) with FLOT chemotherapy as neoadjuvant and adjuvant treatment, then alone as adjuvant treatment, is indicated for 'the treatment of adults with resectable gastric or gastro‑oesophageal junction adenocarcinoma'.

The dosage schedule is available in the summary of product characteristics for durvalumab.

The list price of durvalumab is £592.00 per 2.4-ml vial and £2,466.00 per 10-ml vial (excluding VAT; BNF online, accessed April 2026). The list price of 5-fluorouracil, leucovorin, oxaliplatin and docetaxel varies by pack size and dose.

The company has a commercial arrangement. This makes durvalumab available to the NHS with a discount. The size of the discount is commercial in confidence.

For information, the Carbon Reduction Plan for UK carbon emissions is published on AstraZeneca's webpage on sustainability.